Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Nonlinear Dynamics Sell 2D Systems to Korean Proteome Center

NEW YORK, May 30-PerkinElmer Life Science and Nonlinear Dynamics have sold two 2D gel software systems to the Yonsei Proteome Research Center in Korea, the companies said today.


The sale is the first of this product in the Asian region.


PerkinElmer agreed in July 2001 to be the nonexclusive worldwide distributor for Nonlinear Dynamics bioinformatics products.


Progenesis, introduced last year, is an automated gel analysis software system for 2D electrophoresis. It automates and standardizes the process of gel separations.


The Yonsei Proteome Research Center is at Yonsei University in Seoul, Korea. It was established in March 2000 and serves as a national core facility for proteomics research. It is conducting joint research programs with the Australian Proteome Analysis Facility, Applied Biosystems' Proteomics Research Center, and protein researchers at Osaka University.


Nonlinear Dynamics is a bioinformatics company based in Newcastle-upon-Tyne in the United Kingdom.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.